2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Serum levels of inflammatory mediators as prognostic biomarker in silica exposed workers

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Silicosis is a diffuse interstitial lung disease caused by sustained inhalation of silica and silicates. Several cytokines are activated by their inhalation and can mediate the process of pulmonary fibrosis. The identification of biomarkers could allow an early diagnosis before the development of radiological alterations and help monitor the evolution of patients. The objetive of this study was to determine the clinical significance of specific biomarkers, to estimate their association with the development, severity and/or progression of silicosis, and identify determinants of this evolution. We conducted a prospective observational study in patients attending the pulmonology clinic from 2009 to 2018. Serum levels of the following inflammatory mediators were assessed: interleukin-6 (IL-6), interleukin 2 receptor subunit alpha (IL2R) interleukin 1 beta (IL1B), interleukin-8 (IL-8), tumour necrosis factor-alpha (TNF-α), transforming growth factor-beta1 (TGF-β1), alpha-1 antitrypsin (AAT), C-reactive protein (CRP), lactate dehydrogenase (LDH) and ferritin in subjects exposed to silica, with and without silicosis. Association between those inflammatory mediators with lung function measurements and radiological severity of disease and their impact on prognosis were analysed. 337 exposed to silica (278 with silicosis) and 30 subjects in the control group were included. IL-8, α1AT, ferritin, CRP and LDH levels were higher in silicosis than in those exposed to silica without silicosis. IL-8, LDH and AAT levels were associated with progression of silicosis and IL-6, IL-8, LDH, AAT, ferritin, and CRP with vital status. The results of the ROC analysis indicated the potential of IL-8 as a biomarker in the presence of silicosis and for the prediction of mortality.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

          The objective of this study was to develop a prospectively applicable method for classifying comorbid conditions which might alter the risk of mortality for use in longitudinal studies. A weighted index that takes into account the number and the seriousness of comorbid disease was developed in a cohort of 559 medical patients. The 1-yr mortality rates for the different scores were: "0", 12% (181); "1-2", 26% (225); "3-4", 52% (71); and "greater than or equal to 5", 85% (82). The index was tested for its ability to predict risk of death from comorbid disease in the second cohort of 685 patients during a 10-yr follow-up. The percent of patients who died of comorbid disease for the different scores were: "0", 8% (588); "1", 25% (54); "2", 48% (25); "greater than or equal to 3", 59% (18). With each increased level of the comorbidity index, there were stepwise increases in the cumulative mortality attributable to comorbid disease (log rank chi 2 = 165; p less than 0.0001). In this longer follow-up, age was also a predictor of mortality (p less than 0.001). The new index performed similarly to a previous system devised by Kaplan and Feinstein. The method of classifying comorbidity provides a simple, readily applicable and valid method of estimating risk of death from comorbid disease for use in longitudinal studies. Further work in larger populations is still required to refine the approach because the number of patients with any given condition in this study was relatively small.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            ATS statement: guidelines for the six-minute walk test.

            (2002)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Targeting Interleukin-6 Signaling in Clinic

              Interleukin-6 (IL-6) is a pleiotropic cytokine with roles in immunity, tissue regeneration, and metabolism. Rapid production of IL-6 contributes to host defense during infection and tissue injury, but excessive synthesis of IL-6 and dysregulation of IL-6 receptor signaling is involved in disease pathology. Therapeutic agents targeting the IL-6 axis are effective in rheumatoid arthritis, and applications are being extended to other settings of acute and chronic inflammation. Recent studies reveal that selective blockade of different modes of IL-6 receptor signaling has different outcomes on disease pathology, suggesting novel strategies for therapeutic intervention. However, some inflammatory diseases do not seem to respond to IL-6 blockade. Here, we review the current state of IL-6-targeting approaches in the clinic and discuss how to apply the growing understanding of the immunobiology of IL-6 to clinical decisions.
                Bookmark

                Author and article information

                Contributors
                josejesus.blanco.perez@sergas.es
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                25 June 2021
                25 June 2021
                2021
                : 11
                : 13348
                Affiliations
                [1 ]GRID grid.411855.c, ISNI 0000 0004 1757 0405, Department of Pneumonology, , University Hospital Complex of Vigo, ; Pontevedra, Spain
                [2 ]IRIDIS Group (Investigation in Rheumatology and Immuno-Mediated Diseases) Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, Spain
                [3 ]GRID grid.411048.8, ISNI 0000 0000 8816 6945, Department of Pharmacy, , University Hospital Complex of Santiago de Compostela, ; Santiago de Compostela, Spain
                [4 ]GRID grid.411048.8, ISNI 0000 0000 8816 6945, Department of Clinical Analysis, , University Hospital Complex of Santiago de Compostela (CHUS)-SERGAS, ; Santiago de Compostela, Spain
                [5 ]GRID grid.488911.d, ISNI 0000 0004 0408 4897, Instituto de Investigación Sanitaria (IDIS), ; Santiago de Compostela, Spain
                [6 ]GRID grid.411855.c, ISNI 0000 0004 1757 0405, Department of Pneumonology, , University Hospital Complex of Vigo, ; Pontevedra, Spain
                [7 ]Methodology and Statistics Unit, Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, Spain
                [8 ]GRID grid.411855.c, ISNI 0000 0004 1757 0405, Department of Radiology, , University Hospital Complex of Vigo, ; Pontevedra, Spain
                [9 ]GRID grid.411048.8, ISNI 0000 0000 8816 6945, Department of Pneumonology, , University Hospital Complex of Santiago de Compostela, Spanish Biomedical Research Networking Centre-CIBERES, ; Santiago de Compostela, Spain
                Article
                92587
                10.1038/s41598-021-92587-0
                8233419
                34172787
                bd8ff0b7-6dd4-4494-bcc0-edcc78be949c
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 26 February 2021
                : 7 June 2021
                Funding
                Funded by: Spanish Society of Pneumo (SEPAR), through the SEPAR Research Grants
                Award ID: Project number 779, 2018
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2021

                Uncategorized
                health occupations,medical research
                Uncategorized
                health occupations, medical research

                Comments

                Comment on this article